PROMOTION OF NERVE REGENERATION BY FRAGMENTS OF L1

Information

  • Research Project
  • 2798611
  • ApplicationId
    2798611
  • Core Project Number
    R41HD037353
  • Full Project Number
    1R41HD037353-01
  • Serial Number
    37353
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1999 - 25 years ago
  • Project End Date
    8/31/2000 - 24 years ago
  • Program Officer Name
    QUATRANO, LOUIS A
  • Budget Start Date
    9/1/1999 - 25 years ago
  • Budget End Date
    8/31/2000 - 24 years ago
  • Fiscal Year
    1999
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/30/1999 - 25 years ago
Organizations

PROMOTION OF NERVE REGENERATION BY FRAGMENTS OF L1

DESCRIPTION: (adapted from applicant's abstract) Injuries to the central nervous system (CNS) are among the most devastating and costly of human afflictions. Recent advances in science and technology now provide tools which, for the first time, permit methodical approaches to repair or regenerate damaged CNS axons. Such tools include, among others, a variety of neurotrophic and signaling factors, cell adhesion molecules, disinhibiting agents, cell and gene-based therapies, and reliable animal models of neurotrama. Several laboratories have reported encouraging progress in applying such interventions to enhance axonal regeneration and functional recovery following CNS injury. A key challenge in the development of such therapies is the application of potent bioactive factors that promote nerve regeneration in vivo. L1 is a neuronal cell adhesion molecule (CAM) that is a potent promoter of axonal growth in culture. Phase I of this grant proposes to synthesize fragments of human L1 as Fc fusion proteins and test their ability to promote neurite outgrowth in culture. The L1 fusion proteins will then be tested for functional recovery in a model for acute spinal cord injury in the rat. The Phase I studies are preparatory to a Phase II program in which we will systematically evaluate the activities of various forms of human L1-Fc, optimize the dosage of these molecules in vivo, and explore the efficacy of L1-Fc in a model for chronic spinal cord injury. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT
  • Activity
    R41
  • Administering IC
    HD
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    865
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
  • Organization Name
    ACORDA THERAPEUTICS, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    HAWTHORNE
  • Organization State
    NY
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    10532
  • Organization District
    UNITED STATES